Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial.
McCurdy S, Keedy K, Lawrence L, Nenninger A, Sheets A, Quintas M, Cammarata S. McCurdy S, et al. Antimicrob Agents Chemother. 2020 Feb 21;64(3):e01949-19. doi: 10.1128/AAC.01949-19. Print 2020 Feb 21. Antimicrob Agents Chemother. 2020. PMID: 31844013 Free PMC article.
In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections.
McCurdy S, Lawrence L, Quintas M, Woosley L, Flamm R, Tseng C, Cammarata S. McCurdy S, et al. Antimicrob Agents Chemother. 2017 Aug 24;61(9):e00772-17. doi: 10.1128/AAC.00772-17. Print 2017 Sep. Antimicrob Agents Chemother. 2017. PMID: 28630189 Free PMC article. Clinical Trial.
Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone.
Pfaller MA, Flamm RK, McCurdy SP, Pillar CM, Shortridge D, Jones RN. Pfaller MA, et al. Among authors: mccurdy sp. J Clin Microbiol. 2018 Jul 26;56(8):e00339-18. doi: 10.1128/JCM.00339-18. Print 2018 Aug. J Clin Microbiol. 2018. PMID: 29848564 Free PMC article.
Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.
McCurdy S, Nenninger A, Sheets A, Keedy K, Lawrence L, Quintas M, Cammarata S. McCurdy S, et al. Int J Infect Dis. 2020 Aug;97:374-379. doi: 10.1016/j.ijid.2020.06.018. Epub 2020 Jun 10. Int J Infect Dis. 2020. PMID: 32534142 Free article. Clinical Trial.
New Antimicrobial Agents  …  but No Susceptibility Tests!
Ambler JE, Krause KM, Steenbergen JN, Scangarella-Oman NE, Miller LA, Bhagwat SS, Serio AW, Chesnel L, Mahoney NM, Motyl MR, Critchley IA, Iaconis JP, Stone GG, Alder J, Xerri L, McCurdy SP, van Veenhuyzen DF, Grossman T, Echols RM, Williams G, Bradford PA. Ambler JE, et al. Among authors: mccurdy sp. Clin Infect Dis. 2016 Dec 1;63(11):1530-1531. doi: 10.1093/cid/ciw603. Epub 2016 Aug 31. Clin Infect Dis. 2016. PMID: 27581762 No abstract available.
343 results